Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis

Medicine (United States)

Volumn 95, Issue 32, 2016, Pages

  Sawangjit, Ratree ^a,b   Chongmelaxme, Bunchai ^c   Phisalprapa, Pochamana ^d   Saokaew, Surasak ^b,c,e   Thakkinstian, Ammarin ^f   Kowdley, Kris V ^g   Chaiyakunapruk, Nathorn ^b,c,h,i  

^a MAHASARAKHAM UNIVERSITY   (Thailand)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

^c NARESUAN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF PHAYAO   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g SWEDISH MEDICAL CENTER   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

fibrosis; GRADE; histological outcome; NAFLD; NASH; network meta analysis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETAINE; METADOXINE; METFORMIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PHOSPHOLIPID; PIOGLITAZONE; PLACEBO; POLYUNSATURATED FATTY ACID; ROSIGLITAZONE; TELMISARTAN; THIOCTIC ACID; TRYPTOPHAN; URSODEOXYCHOLIC ACID; VALSARTAN; 2,4-THIAZOLIDINEDIONE; CHENODEOXYCHOLIC ACID;

ABDOMINAL CRAMP; BLOATING; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; HEARTBURN; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; META ANALYSIS; META ANALYSIS (TOPIC); MORTALITY; NAUSEA AND VOMITING; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; SYSTEMATIC REVIEW; WEIGHT CONTROL; ANALOGS AND DERIVATIVES; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

ANTIOXIDANTS; CHENODEOXYCHOLIC ACID; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PENTOXIFYLLINE; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VITAMIN E;

EID: 84983419781     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004529     Document Type: Review

References (82)

1. Chalasani N, Younossi Z, Lavine J, et al. AASLD practice guideline. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;5:2005-23
2. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 2015;45:363-77
3. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 2015;13:2062-70
4. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73
5. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13: 643-654.e641-649; quiz e639-640
6. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609
7. Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104
8. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65
9. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in nonalcoholic fatty liver disease (NAFLD): a systematic review and metaanalysis of randomised trials. Diabetologia 2012;55:885-904
10. Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Hepatol 2012;56:944-51
11. Mahady SE,Webster AC, Walker S, et al. The role of thiazolidinediones in non-alcoholic steatohepatitis-A systematic review and meta-analysis. J Hepatol 2011;55:1383-90
12. Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012;35:66-75
13. Zeng T, Zhang CL, Zhao XL, et al. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized doubleblind, placebo-controlled studies. Eur J Gastroenterol Hepatol 2014; 26:646-53
14. Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308: 1246-53
15. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7
16. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Inter Med 2015;162:777-84
17. Hutton B, Salanti G, Chaimani A, et al. The quality of reporting methods and results in network metaanalyses: an overview of reviews and suggestions for improvement. PLoS One 2014;9:e92508
18. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630
19. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6
20. Higgins J, Altman D, Sterne J. Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JPT, editor. Available at: http:// www.cochrane-handbook.org. The Cochrane Collaboration. 2011 (accessed June 10, 2015)
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
22. Maldonado JR, Wysong A, van der Starre PJ, et al. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. Psychosomatics 2009;50:206-17
23. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44
24. Mavridis D, Salanti G. Exploring and accounting for publication bias in mental health: a brief overview of methods. Evid Based Ment Health 2014;17:11-5
25. Dechartres A, Altman DG, Trinquart L, et al. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 2014;312:623-30
26. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21
27. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74
28. Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009;50:1818-26
29. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84
30. Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015;62:190-7
31. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
32. Celinski K, Konturek PC, Slomka M, et al. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease-14 months follow up. J Physiol Pharmacol 2014; 65:75-82
33. Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015;49:137-44
34. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-43
35. Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated nonalcoholic steatohepatitis. World J Gastroenterol 2009;15:942-54
36. Gianturco V, Troisi G, Bellomo A, et al. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int 2013;7:570-6
37. Han Y, Shi JP, Ma AL, et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig 2014;34:1-7
38. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90
39. Haukeland JW, Konopski Z, Eggesbo HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60
40. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulinsensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-8
41. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305:1659-68
42. Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-32
43. Lee YM, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc 2012;76:756-60
44. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52:472-9
45. Li YH, Yang LH, Sha KH, et al. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol 2015;21:7008-13
46. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8
47. Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 2012;52:1658-65
48. Loomba R, Sirlin CB, Ang B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015;61:1239-50
49. Malaguarnera M, Gargante MP, Russo C, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis-A randomized and controlled clinical trial. Am J Gastroenterol 2010; 105:1338-45
50. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebocontrolled trial. J Clin Gastroenterol 2009;43:990-4
51. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28
52. Nogueira MA, Oliveira CP, Ferreira Alves VA, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2016;35: 578-86
53. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18-23
54. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9
55. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-10
56. Rinella ME, Koppe S, Brunt E, et al. Pentoxifylline improves ALT and histology in patients with NASH, a double blind placebo controlled trial. AGA. Abstract No. 563. 2009(563):A88-89
57. Sanyal AJ, Abdelmalek MF, Suzuki A, et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377-84
58. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362: 1675-85
59. Sanyal AJ,Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-15
60. Sharma BC, Kumar A, Garg V, et al. A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis. J Clin Exp Hepatol 2012;2:333-7
61. Shenoy KT, Balakumaran LK, Mathew P, et al. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. J Clin Exp Hepatol 2014;4:94-100
62. Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Ther Adv Gastroenterol 2009;2:157-63
63. Sturm N, Bronowicki JP, Maynard-Muet M, et al. Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. Gastroenterol Clin Biol 2009;33:984-6
64. Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014;57:878-90
65. Torres DM, Jones FJ, Shaw JC, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011;54:1631-9
66. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44
67. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011;10:277-86
68. Vilar Gomez E, Rodriguez Miranda A, Gra Oramas B, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009;30:999-1009
69. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-9
70. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44
71. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7
72. Singh S, Khera R, Allen AM, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015;62: 1417-32
73. BerryD,WathenJK,NewellM.Bayesianmodel averaging inmeta-analysis: vitamin E supplementation and mortality. Clin Trials 2009; 6:28-41
74. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis JAMA 2007;297:842-57
75. Dietrich M, Jacques PF, PencinaMJ, et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 2009;205:549-53
76. Gerss J, Kopcke W. The questionable association of vitamin E supplementation and mortality-inconsistent results of different metaanalytic approaches. Cell Mol Biol 2009;55(Suppl):1111-20
77. Mitka M. FDA eases restrictions on the glucose-lowering drug rosiglitazone. JAMA 2013;310:2604
78. Lincoff A, Wolski K, Nicholls S, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A metaanalysis of randomized trials. JAMA 2007;298:1180-8
79. Du J, Ma YY, Yu CH, et al. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2014;20: 569-77
80. Ji HF, Sun Y, Shen L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis. Nutrition 2014;30:986-91
81. Xiang Z, Chen YP, MaKF, et al. The role of ursodeoxycholic acid in nonalcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13:140
82. Sanyal AJ, Friedman SL, McCullough AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology 2015;61:1392-405